References
- Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol. Online J. 15(11), 1 (2009).
- Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J. Clin. 60(5), 301–316 (2010).
- Cochran AJ, Starz H, Ohsie SJ, Sarantopoulos GP, Haas CJ, Binder S. Pathologic reporting and special diagnostic techniques for melanoma. Surg. Oncol. Clin. N. Am. 15(2), 231–251 (2006).
- Vysis Melanoma FISH Probe Kit, package insert, Abbott Molecular, IL, USA.
- Ubel PA, Jepson C, Baron J, Hershey JC, Asch DA. The influence of cost–effectiveness information on physicians’ cancer screening recommendations. Soc. Sci. Med. 56(8), 1727–1736 (2003).
- McKenna DB, Lee RJ, Prescott RJ, Doherty VR. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision. Br. J. Dermatol. 150(3), 523–530 (2004).
- McGinnis KS, Lessin SR, Elder DE et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch. Dermatol. 138(5), 617–621 (2002).
- Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur. J. Cancer 46(2), 270–283 (2010).
- Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 3(3), 159–165 (2002).
- Markovic SN, Erickson LA, Rao RD et al.; Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc. 82(3), 364–380 (2007).
- Crawford M, Mauro A, Church J. Consumer price index detailed report: data for July 2010 (2010).
- Beusterien KM, Szabo SM, Kotapati S et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br. J. Cancer 101(3), 387–389 (2009).
- Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: a cost–effectiveness analysis. J. Am. Acad. Dermatol. 41(5 Pt 1), 738–745 (1999).
- Losina E, Walensky RP, Geller A et al. Visual screening for malignant melanoma: a cost–effectiveness analysis. Arch. Dermatol. 143(1), 21–28 (2007).
- Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J. Surg. Oncol. 67(4), 228–233 (1998).
Websites
- Surveillance Epidemiology and End Results (SEER) Program. SEER Data, 1973–2007. (2010). http://seer.cancer.gov/data
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Melanoma (V.2.2012). Fort Washington, PA: National Comprehensive Cancer Network; 2012. www.pnlab.org/clinical/documents/melanoma.pdf
- Social Security Administration. Period Life Table, 2006 for the Social Security Area Population. (2010). www.ssa.gov/oact/STATS/table4c6.html.
- Centers for Medicare and Medicaid Services (CMS). Medicare Fee for Service Payment. Physician Fee Schedule National Payment Amount 2010 File. Centers for Medicare and Medicaid Services (CMS); 2010. www.cms.gov/apps/physician-fee